Ken Waterman received his B.S. degree with honors in chemistry from UCLA and his Ph.D. in physical-organic chemistry from UC Berkeley. He conducted post-doctoral studies on the physical chemistry of interfaces as an NIH research fellow at Columbia University.
In 1987, Dr. Waterman began a 12-year career at Polaroid (Massachusetts) where he invented and brought to market a number of both photographic and non-silver-based imaging products.
In 1999, he joined the Pharmaceutical Sciences Division at Pfizer (Connecticut), rising to the rank of Research Fellow. His focus at Pfizer included drug stability, drug delivery technology, biopharmaceutics and prodrug development. His work on accelerated stability and oxygen absorbers was dramatically successful and has influenced the entire industry.
His drug delivery technology inventions have allowed several drugs to advance through clinical trials. He is the author of over 70 journal articles, book chapters, and US patents, and is on the editorial board of Pharmaceutical Development and Technology.
In 2011, he started FreeThink Technologies, Inc. which developed and markets ASAPprime® stability modeling software. FreeThink's laboratories conduct analytical studies for companies and carry out R&D in a number of fields.
In 2011, he was also made an American Association of Pharmaceutical Sciences Fellow. Dr. Waterman is a frequent speaker at international conferences and universities.
Mark Kastan received his undergraduate degree in Economics from Washington University in St. Louis and his MBA from the Simon Graduate School of Business at the University of Rochester.
Mark is a Wall Street veteran with 17 years of experience as an equity analyst, highlighted by 9 years covering competitive telecom companies at both Credit Suisse First Boston and Merrill Lynch.
Mark was best known for his coverage of the CLEC industry and was consistently ranked as one of the top CLEC analysts by both "Institutional Investor" magazine and Greenwich Associates.
During his tenure on Wall Street, Mark advised and consulted with many early stage companies in the construction and implementation of business plans. Many of these companies subsequently pursued successful debt and equity offerings.
Alisa Waterman received her B.A. degree in biology from Wesleyan University, her Ph.D. in cell biology from Albert Einstein College of Medicine and completed post-doctoral studies in biochemistry and cell biology as a Jane Coffin Childs Fellow at Yale University School of Medicine.
Dr. Waterman worked for 24 years at Boehringer Ingelheim Pharmaceuticals (as a Senior Research Fellow) championing discovery and development of both biological and small molecule drug candidates.
In 2015, she joined FreeThink Technologies, Inc. as Chief Science Officer responsible for both research strategy and leading company projects.
Jennifer Lewis received her B.A. degree in chemistry from Berea College and her Ph.D. in bioanalytical chemistry from the University of Kentucky.
Dr. Lewis is responsible for all aspects of laboratory management, direct client-sponsored project work, and helping develop and spearhead FreeThink’s R&D strategy.
Dr. Lewis has extensive experience acting as an analytical lead on multidisciplinary teams to support new product development and existing product optimization in the pharmaceutical industry. She has expertise in a wide range of analytical methodologies to support product release testing, stability testing, new product formulation, patent protection and unknown impurity/degradant identification.
Dr. Lewis has developed and validated test methods, particularly chromatography methods, for both small molecule drugs and biologics in a cGMP environment. Most recently, she fulfilled an administrative role as an Assistant Dean of Strategic Initiatives, creating new professional degree programs at the College of Arts and Sciences, University of Miami.
Jennifer Chu received her B.S.E degree in chemical engineering from Princeton University and her M.S. and Ph.D. in chemical engineering from The University of Texas at Austin.
Dr. Chu is responsible for the management of FreeThink’s internal research and technology development projects including the progress of the external scientific publications plan. Dr. Chu is accountable for client-sponsored project work and formulation development strategies.
Dr. Chu's experience ranges with a variety of dosage forms. Including immediate release and modified release tablets. This extends to capsules, soft gels, oral liquids, and injectables.
Prior to joining Free Think Technologies in 2018, Dr. Chu directed pharmaceutical development and processing, while also an established leader in the cutting-edge biotech industry. Most recently, she was the Executive Director Pharmaceutical Sciences for Achillion Pharmaceuticals, Inc., and spent 7 years at Pfizer in Pharmaceutical R&D.